Amplifica is a preclinical stage biopharmaceutical company dedicated to developing innovative treatments for androgenic alopecia, commonly known as hair loss. The company employs a nature-inspired scientific approach, focusing on a molecular mechanism designed to promote the regrowth of natural hair. Amplifica has successfully identified and isolated unique signaling molecules that stimulate hair follicles, offering healthcare professionals effective solutions for treating hair loss.
Orchestra BioMed, Inc. is a biomedical innovation company established in 2017 and located in New Hope, Pennsylvania. The company is dedicated to developing high-impact therapeutic solutions for medical procedures, with a primary focus on addressing cardiovascular diseases, which account for a significant number of global fatalities annually. Orchestra BioMed aims to accelerate the commercialization of its products through strategic partnerships with medical device companies. Its leading product candidates include BackBeat Cardiac Neuromodulation Therapy, designed for hypertension treatment, and Virtue Sirolimus AngioInfusion Balloon, which targets atherosclerotic artery disease. By emphasizing evidence-based solutions, Orchestra BioMed seeks to improve patient outcomes for serious medical conditions.
Psudo is a footwear company based in Saint Louis, Missouri, that specializes in manufacturing sustainable sneakers. Founded in 2021, the company utilizes locally sourced materials and eco-friendly recycled fabrics to create lightweight and affordable shoes. Psudo's sneakers are designed to provide antimicrobial properties and anatomically supportive features, ensuring comfort for all-day wear. Through its commitment to sustainability, Psudo aims to offer a diverse range of eco-conscious footwear options for consumers.
Outstanding Foods, Inc. is a Los Angeles-based company specializing in plant-based vegan snacks. Founded in 2015 and rebranded from Fresh Soul Holdings, Inc. in 2017, the company offers products under the PigOut Rinds and TakeOut Puffs brands. Renowned vegetarian chef Dave Anderson crafts the snacks using his proprietary culinary methods, ensuring that each product is made from pure, wholesome ingredients. Notably, the company's flagship offering includes plant-based bacon chips that are free from animal ingredients and artificial additives, allowing consumers to enjoy flavorful snacks without guilt. Outstanding Foods aims to provide delicious, nutritious options for those seeking healthier alternatives in the snack food market.
Aerami Therapeutics is a biopharmaceutical company dedicated to developing innovative inhaled therapies for chronic diseases, particularly diabetes. The company specializes in a proprietary handheld soft mist device that facilitates the efficient delivery of insulin directly into the lungs, enabling patients to achieve high lung deposition with minimal effort. This device aims to offer a more convenient and effective alternative to traditional injection methods for insulin administration. Founded in 2010 and based in Durham, North Carolina, Aerami Therapeutics continues to focus on advancing its technology to improve patient outcomes in managing diabetes and other chronic conditions.
Aerami Therapeutics is a biopharmaceutical company dedicated to developing innovative inhaled therapies for chronic diseases, particularly diabetes. The company specializes in a proprietary handheld soft mist device that facilitates the efficient delivery of insulin directly into the lungs, enabling patients to achieve high lung deposition with minimal effort. This device aims to offer a more convenient and effective alternative to traditional injection methods for insulin administration. Founded in 2010 and based in Durham, North Carolina, Aerami Therapeutics continues to focus on advancing its technology to improve patient outcomes in managing diabetes and other chronic conditions.
DermaSensor, Inc. develops a hand-held device that uses artificial intelligence to evaluate skin lesions for cancer. It offers DermaSensor, a device that allows physicians and consumers to perform skin checks in physician offices and patient homes. The company’s device is also used for lesion identification, scanning, photon scattering, and algorithmic analysis. DermaSensor, Inc. was founded in 2009 and is based in Miami, Florida.
Viscient Biosciences is a biotechnology company working at the intersection of human 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics) analysis to develop drugs across a range of therapeutic areas, with an initial focus in non-alcoholic steatohepatitis (NASH,“fatty liver disease”).
Founded and staffed by a team composed of former Organovo and Ardea Biosciences scientists and entrepreneurs, Viscient is driving a revolution in drug discovery, overthrowing the old paradigm of discovery in animal models.
Zoomcar India Private Ltd. is a prominent self-drive car rental service based in Bengaluru, India. Founded in 2012, the company offers a wide range of vehicles, including SUVs, luxury cars, electric cars, and sedans, available for rent by the hour, day, week, or month. Zoomcar operates an online platform that allows customers to easily book cars using their mobile phones, providing a hassle-free rental experience. With approximately 21,000 vehicles registered on its platform, Zoomcar primarily generates revenue from short-term self-drive rentals and vehicle subscriptions, with the majority of its business concentrated in India. The company also has a strategic partnership with Godrej Consumer Products Limited and has expanded its operations to several countries, including Egypt, Indonesia, Vietnam, and the Philippines.
Hydrobuilder.com offers a large selection of indoor grow lights, complete hydroponic system, plant nutrients, ventilation systems, grow tents and more! Hydrobuilder supplies both hobby and commercial cultivators in all 50 states.
Zoomcar India Private Ltd. is a prominent self-drive car rental service based in Bengaluru, India. Founded in 2012, the company offers a wide range of vehicles, including SUVs, luxury cars, electric cars, and sedans, available for rent by the hour, day, week, or month. Zoomcar operates an online platform that allows customers to easily book cars using their mobile phones, providing a hassle-free rental experience. With approximately 21,000 vehicles registered on its platform, Zoomcar primarily generates revenue from short-term self-drive rentals and vehicle subscriptions, with the majority of its business concentrated in India. The company also has a strategic partnership with Godrej Consumer Products Limited and has expanded its operations to several countries, including Egypt, Indonesia, Vietnam, and the Philippines.
Outstanding Foods, Inc. is a Los Angeles-based company specializing in plant-based vegan snacks. Founded in 2015 and rebranded from Fresh Soul Holdings, Inc. in 2017, the company offers products under the PigOut Rinds and TakeOut Puffs brands. Renowned vegetarian chef Dave Anderson crafts the snacks using his proprietary culinary methods, ensuring that each product is made from pure, wholesome ingredients. Notably, the company's flagship offering includes plant-based bacon chips that are free from animal ingredients and artificial additives, allowing consumers to enjoy flavorful snacks without guilt. Outstanding Foods aims to provide delicious, nutritious options for those seeking healthier alternatives in the snack food market.
DarioHealth Corp. is a digital health company that specializes in developing and commercializing proprietary technology for laboratory testing via smartphones and mobile devices. Its flagship product, the Dario Smart Diabetes Management Solution, integrates a cloud-based software application with a compact blood glucose monitoring device. This solution enables users to manage their diabetes through real-time data tracking, coaching, and support, while also providing alerts and analysis of health trends. DarioHealth markets its products directly to consumers and through retail pharmacies, hospitals, and online channels. The company also offers a digital platform, DarioEngage, to enhance user engagement and support in managing chronic illnesses. Founded in 2011 and headquartered in Caesarea, Israel, DarioHealth emphasizes personalized, evidence-based interventions driven by data analytics and individual coaching, addressing various health concerns such as diabetes, hypertension, and weight management.
Kintara Pharmaceuticals, Inc. engages in developing and commercializing cancer therapies in orphan and other cancer indications for the treatment of patients failing modern targeted or biologic therapy. The company’s principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. Kintara Pharmaceuticals, Inc. also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. The company was founded in 2010 and is headquartered in Vancouver, Canada.
Outstanding Foods, Inc. is a Los Angeles-based company specializing in plant-based vegan snacks. Founded in 2015 and rebranded from Fresh Soul Holdings, Inc. in 2017, the company offers products under the PigOut Rinds and TakeOut Puffs brands. Renowned vegetarian chef Dave Anderson crafts the snacks using his proprietary culinary methods, ensuring that each product is made from pure, wholesome ingredients. Notably, the company's flagship offering includes plant-based bacon chips that are free from animal ingredients and artificial additives, allowing consumers to enjoy flavorful snacks without guilt. Outstanding Foods aims to provide delicious, nutritious options for those seeking healthier alternatives in the snack food market.
Aerami Therapeutics is a biopharmaceutical company dedicated to developing innovative inhaled therapies for chronic diseases, particularly diabetes. The company specializes in a proprietary handheld soft mist device that facilitates the efficient delivery of insulin directly into the lungs, enabling patients to achieve high lung deposition with minimal effort. This device aims to offer a more convenient and effective alternative to traditional injection methods for insulin administration. Founded in 2010 and based in Durham, North Carolina, Aerami Therapeutics continues to focus on advancing its technology to improve patient outcomes in managing diabetes and other chronic conditions.
DarioHealth Corp. is a digital health company that specializes in developing and commercializing proprietary technology for laboratory testing via smartphones and mobile devices. Its flagship product, the Dario Smart Diabetes Management Solution, integrates a cloud-based software application with a compact blood glucose monitoring device. This solution enables users to manage their diabetes through real-time data tracking, coaching, and support, while also providing alerts and analysis of health trends. DarioHealth markets its products directly to consumers and through retail pharmacies, hospitals, and online channels. The company also offers a digital platform, DarioEngage, to enhance user engagement and support in managing chronic illnesses. Founded in 2011 and headquartered in Caesarea, Israel, DarioHealth emphasizes personalized, evidence-based interventions driven by data analytics and individual coaching, addressing various health concerns such as diabetes, hypertension, and weight management.
Orchestra BioMed, Inc. is a biomedical innovation company established in 2017 and located in New Hope, Pennsylvania. The company is dedicated to developing high-impact therapeutic solutions for medical procedures, with a primary focus on addressing cardiovascular diseases, which account for a significant number of global fatalities annually. Orchestra BioMed aims to accelerate the commercialization of its products through strategic partnerships with medical device companies. Its leading product candidates include BackBeat Cardiac Neuromodulation Therapy, designed for hypertension treatment, and Virtue Sirolimus AngioInfusion Balloon, which targets atherosclerotic artery disease. By emphasizing evidence-based solutions, Orchestra BioMed seeks to improve patient outcomes for serious medical conditions.
Hydrofarm is a manufacturer and distributor of controlled environment agriculture equipment and supplies, primarily serving the United States and Canada. The company offers a wide range of products, including high-intensity grow lights, climate control solutions, premium soils, soil alternatives, nutrients, and various growing equipment. Hydrofarm's product portfolio features both proprietary and distributed brands, ensuring a diverse selection for growers and cultivators. Established in 1977 and headquartered in Petaluma, California, Hydrofarm has over 40 years of experience in the industry. The company's mission focuses on empowering growers by providing high-quality products that enhance efficiency, consistency, and productivity in agricultural projects. Its offerings include lighting systems, hydro components, atmospheric control equipment, and consumable supplies, catering to the needs of various cultivation environments.
Orchestra BioMed, Inc. is a biomedical innovation company established in 2017 and located in New Hope, Pennsylvania. The company is dedicated to developing high-impact therapeutic solutions for medical procedures, with a primary focus on addressing cardiovascular diseases, which account for a significant number of global fatalities annually. Orchestra BioMed aims to accelerate the commercialization of its products through strategic partnerships with medical device companies. Its leading product candidates include BackBeat Cardiac Neuromodulation Therapy, designed for hypertension treatment, and Virtue Sirolimus AngioInfusion Balloon, which targets atherosclerotic artery disease. By emphasizing evidence-based solutions, Orchestra BioMed seeks to improve patient outcomes for serious medical conditions.
BackBeat Medical Inc. is a medical technology company established in 2010, focusing on innovative cardiac stimulation therapies for hypertension and heart failure. The company has developed a patented treatment called programmable hypertension control (PHC) therapy, which utilizes proprietary pacing algorithms that can be integrated into standard pacemakers. This offers a significant therapeutic alternative for hypertension patients, especially those who already have or need a pacemaker. Clinical results from the Moderato™ pacemaker, which incorporates PHC algorithms, indicate a substantial and sustained reduction in blood pressure, with in-office measurements showing an average decrease of 24 mmHg and 24-hour ambulatory measurements averaging a reduction of 14 mmHg from baseline. The effectiveness of this therapy has been demonstrated in clinical follow-ups extending beyond two years for certain patients. BackBeat Medical's PHC therapy is supported by a comprehensive global patent portfolio, underscoring its commitment to advancing treatment options for hypertension.
Aerami Therapeutics is a biopharmaceutical company dedicated to developing innovative inhaled therapies for chronic diseases, particularly diabetes. The company specializes in a proprietary handheld soft mist device that facilitates the efficient delivery of insulin directly into the lungs, enabling patients to achieve high lung deposition with minimal effort. This device aims to offer a more convenient and effective alternative to traditional injection methods for insulin administration. Founded in 2010 and based in Durham, North Carolina, Aerami Therapeutics continues to focus on advancing its technology to improve patient outcomes in managing diabetes and other chronic conditions.
Adgero Biopharmaceuticals is a biopharmaceutical company specializing in photodynamic therapy for the treatment of cancer, particularly focusing on rare and unmet medical needs. The company’s lead product, REM-001 Therapy, utilizes a combination of a laser light source, a light delivery device, and a drug to target cutaneous metastatic cancers, basal cell nevus syndrome, and recurrent basal cell carcinoma. REM-001 has shown promising safety and efficacy in Phase 2/3 clinical trials, particularly in patients with cutaneous metastatic breast cancer who have not responded to radiation therapy. Founded in 2007 and headquartered in Pittstown, New Jersey, Adgero aims to advance its proprietary therapy platform to address serious oncology indications by leveraging existing clinical data to potentially secure regulatory approval for its innovative treatment approach.
Caliber Therapeutics, Inc. engages in the development and commercialization of minimally-invasive balloon-based drug delivery products for the intervention of atherosclerotic diseases. It offers Targeted Angioplasty Drug Delivery balloon, a stent-free delivery platform of anti-restenotic drugs, which enables controlled and targeted drug delivery, reduces thrombosis risk, and reduces the need to implant permanent devices. Caliber Therapeutics, Inc. is based in Monmouth Junction, New Jersey.
Motus GI Holdings, Inc., a medical technology company, provides endoscopy solutions that enhance clinical outcomes and the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions in the United States and Israel. Its flagship product is the Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The company is based in Fort Lauderdale, Florida.
Helocyte Inc. (“Helocyte”), a portfolio company of Fortress Biotech, is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cytomegalovirus (“CMV”). We aim to: (1) secure rights to new technologies via acquisition, licensing, co-development and/or other partnering; (2) fund research and development of new technologies; and (3) ultimately introduce new technologies to market. We are currently progressing three immunotherapies developed in the laboratory of Donald J. Diamond Ph.D., Chair of the Department of Experimental Therapeutics at City of Hope of Duarte, California (“City of Hope”). In March of 2015, Helocyte consummated an exclusive worldwide license and option agreement with City of Hope, acquiring rights to the current Helocyte programs. PepVax, is an HLA-restricted single antigen [UL83 (pp65)] peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant (“HSCT”) recipients. In July of 2015, we opened a Phase 2 study of PepVax in allogeneic HSCT recipients. Our second program, Triplex, is a universal (non-HLA-restricted) recombinant viral vector vaccine expressing three immuno-dominant proteins [UL83 (pp65), UL123 (IE1), UL122 (IE2)] linked to CMV in the post-transplant setting. In November of 2015, we opened a Phase 2 study of Triplex in allogeneic HSCT recipients. We additionally plan to study Triplex in recipients of allogeneic Solid Organ Transplantation. Our third program, Pentamer, is a universal (non-HLA-restricted) recombinant viral vector vaccine expressing five primary subunits of CMV (gH/gL/UL128/UL130/UL131A) linked to viral transmission in utero. The Pentamer program is currently undergoing nonclinical development and will ultimately be studied for prevention of congenital CMV.
Adgero Biopharmaceuticals is a biopharmaceutical company specializing in photodynamic therapy for the treatment of cancer, particularly focusing on rare and unmet medical needs. The company’s lead product, REM-001 Therapy, utilizes a combination of a laser light source, a light delivery device, and a drug to target cutaneous metastatic cancers, basal cell nevus syndrome, and recurrent basal cell carcinoma. REM-001 has shown promising safety and efficacy in Phase 2/3 clinical trials, particularly in patients with cutaneous metastatic breast cancer who have not responded to radiation therapy. Founded in 2007 and headquartered in Pittstown, New Jersey, Adgero aims to advance its proprietary therapy platform to address serious oncology indications by leveraging existing clinical data to potentially secure regulatory approval for its innovative treatment approach.
Kintara Pharmaceuticals, Inc. engages in developing and commercializing cancer therapies in orphan and other cancer indications for the treatment of patients failing modern targeted or biologic therapy. The company’s principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. Kintara Pharmaceuticals, Inc. also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. The company was founded in 2010 and is headquartered in Vancouver, Canada.
Aerami Therapeutics is a biopharmaceutical company dedicated to developing innovative inhaled therapies for chronic diseases, particularly diabetes. The company specializes in a proprietary handheld soft mist device that facilitates the efficient delivery of insulin directly into the lungs, enabling patients to achieve high lung deposition with minimal effort. This device aims to offer a more convenient and effective alternative to traditional injection methods for insulin administration. Founded in 2010 and based in Durham, North Carolina, Aerami Therapeutics continues to focus on advancing its technology to improve patient outcomes in managing diabetes and other chronic conditions.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company based in Norwood, Massachusetts, specializing in the development and commercialization of therapeutics for rare and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a synthetic oral cannabinoid receptor type 2 (CB2) agonist currently in Phase III trials for systemic sclerosis and dermatomyositis, as well as Phase IIb trials for systemic lupus erythematosus and cystic fibrosis. In addition, Corbus is advancing CRB-4001, a peripherally-restricted cannabinoid receptor type 1 (CB1) inverse agonist, targeting conditions such as nonalcoholic steatohepatitis (NASH). Corbus has established a licensing agreement with Jenrin Discovery, LLC, to develop a library of over 600 compounds, and maintains a strategic collaboration with Kaken Pharmaceutical Co., Ltd. for lenabasum's development in Japan. The company was founded in 2009 and demonstrates a commitment to addressing unmet medical needs in its focused therapeutic areas.
Matinas BioPharma is a clinical-stage biopharmaceutical company based in Bedminster, New Jersey, that specializes in the discovery and development of therapeutics for fungal and bacterial infections. The company utilizes a proprietary lipid nano-crystal drug delivery platform, known as cochleate delivery technology, to create orally delivered therapeutics. Its lead product candidate, MAT2203, is an oral formulation of amphotericin B currently in Phase II trials for treating invasive fungal infections. Additionally, Matinas is developing MAT2501, an encochleated formulation of amikacin aimed at addressing multidrug-resistant bacterial infections. The company's pipeline also includes MAT9001, an omega-3 fatty acid formulation for hypertriglyceridemia, and it is exploring options for its MAT8800 discovery program targeting non-alcoholic fatty liver disease. Matinas has established research collaborations with notable organizations, including the National Institute of Neurological Disorders and Stroke and ViiV Healthcare, to advance its therapeutic developments.
Deem, Inc. is a technology platform based in San Francisco that specializes in solutions for the business travel industry, offering a range of applications for travel, car service, and expense management. Founded in 1999, Deem provides Commerce-as-a-Service (CaaS) to businesses, enabling them to streamline travel bookings and manage expenses efficiently. Its integrated cloud suite allows corporations to control costs, as employees can easily book flights, hotels, and ground transportation, while keeping spending within policy. Additionally, Deem facilitates merchants in promoting their products and services through various consumer engagement strategies, enhancing customer loyalty and broadening market reach. As of January 2019, Deem operates as a subsidiary of Enterprise Holdings, Inc.
Armada Water Assets is a Houston-based company that specializes in water supply, collection, and remediation services. Established in 2012, it focuses on the safe and cost-effective management of contaminated water generated from conventional oil and gas production, as well as from hydraulic fracturing activities. The company provides a comprehensive range of services, including the collection, handling, transport, treatment, and reuse of produced water and flow-back water, ensuring that these processes meet environmental standards while supporting the energy industry's operational needs.
DarioHealth Corp. is a digital health company that specializes in developing and commercializing proprietary technology for laboratory testing via smartphones and mobile devices. Its flagship product, the Dario Smart Diabetes Management Solution, integrates a cloud-based software application with a compact blood glucose monitoring device. This solution enables users to manage their diabetes through real-time data tracking, coaching, and support, while also providing alerts and analysis of health trends. DarioHealth markets its products directly to consumers and through retail pharmacies, hospitals, and online channels. The company also offers a digital platform, DarioEngage, to enhance user engagement and support in managing chronic illnesses. Founded in 2011 and headquartered in Caesarea, Israel, DarioHealth emphasizes personalized, evidence-based interventions driven by data analytics and individual coaching, addressing various health concerns such as diabetes, hypertension, and weight management.
GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, dedicated to developing therapeutic products for cancer and infectious diseases through its proprietary Tarmogen platform. The company’s pipeline includes GS-4774, currently in Phase 2 trials for hepatitis B virus treatment, and various candidates targeting cancer, such as GI-6207 for medullary thyroid cancer, GI-6301 for tumors expressing the brachyury protein, and GI-4000 for resected pancreatic cancer. Additionally, GlobeImmune is advancing several candidates for infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D virus, currently in preclinical stages. The Tarmogen platform also includes products designed to address challenges in cancer therapy, such as preventing the emergence of mutated escape variants. The company has established strategic collaborations with Gilead Sciences and Celgene Corporation. Originally founded as Ceres Pharmaceuticals in 1995, GlobeImmune changed its name in 2001 to reflect its focus on innovative immunotherapy solutions.
Organovo Holdings, Inc. is a biotechnology company based in Solana Beach, California, specializing in the development of bioprinted human tissues using its innovative 3D human tissue platform technology. This platform features proprietary NovoGen Bioprinters, which create living tissues from mammalian cells, along with technologies for bio-inks and complex multicellular structures. Organovo offers ExVive human liver and kidney tissues, which are utilized for predictive preclinical drug testing. Additionally, the company is working on in vivo liver tissues aimed at treating severe liver diseases and developing NovoTissues liver products using cells from both liver and umbilical cord donors. Founded in 2007, Organovo aims to address unmet medical needs through its advanced tissue engineering capabilities, contributing to the field of regenerative medicine.
InVivo Therapeutics is a research and clinical-stage biotechnology company based in Cambridge, Massachusetts, specializing in the development of biopolymer scaffolding devices for spinal cord injuries. Founded in 2005, the company emerged from research conducted at prestigious institutions, including the Massachusetts Institute of Technology and Harvard's Brigham and Women's Hospital. Its primary product, the Neuro-Spinal Scaffold, is an investigational bioresorbable polymer designed to be implanted at the site of spinal cord injuries to facilitate recovery and restore function in affected individuals. InVivo Therapeutics is advancing both clinical and preclinical development programs, targeting acute and chronic spinal cord injuries, with the goal of improving outcomes for patients suffering from paralysis due to trauma.
PROLOR Biotech is developing proprietary versions of already-approved therapeutic proteins. The Company’s Carboxyl Terminal Peptide technology can be attached to an array of existing therapeutic proteins, stabilizing the therapy in the bloodstream and extending its lifespan without additional toxicity or loss of desired biological activity. PROLOR products under development include Human Growth Hormone (“hGH”) for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone (a $3 billion market opportunity). PROLOR’s hGH could potentially be injected once a week or twice per month instead of daily. PROLOR’s hGH is scheduled for Phase III trials in 2013.